Osteoprotegerin (OPG) in Induced Chronic Obstructive Pulmonary Disease (COPD) Sputum

Osteoprotegerin (OPG) is a secreted glycoprotein containing 401 amino acids. It is a member of the tumour necrosis factor (TNF) receptor superfamily. It was firstly discovered as a protein regulating bone metabolism, inhibiting osteoclastogenesis, consequently, inhibiting bone resorption OPG is detected in lung using Northern blot analysis. It is likely that OPG would contribute to the pathogenesis of COPD and could be an effective disease marker of the disease

Inclusion criteria

• Healthy non-smokers

• Age <35 years (younger group)
• Aged matched to COPD patients (older group)
• Normal spirometry
• Subjects are able to give informed consent
• Healthy smokers

• Age <35 years (younger group)
• Aged matched to COPD patients (older group)
• Normal spirometry
• Subjects are able to give informed consent Stable COPD patients: Stage I-IV according to the GOLD guidelines (3), (9)
• Current and/or ex-smokers with no less than 10 pack-year smoking history
• The subjects are able to give informed consent COPD patients with acute exacerbation: Stage I-IV according to the GOLD guidelines (3), (9)
• Exacerbation of COPD defined as "an event in the natural course of the disease characterised by a change in the patient's baseline dyspnoea, cough and/or sputum beyond day to day variability sufficient to warrant a change in management" (9)
• Current and/or ex-smokers with no less than 10 pack-year smoking history
• The subjects are able to give informed consent Asthma patients
• Patients diagnosed with asthma
• The subjects are able to give informed consent Bronchiectasis patients
• Patients with CT-confirmed bronchiectasis
• The subjects are able to give informed consent Cystic fibrosis patients
• Patients diagnosed with cystic fibrosis
• The subjects are able to give informed consent

Exclusion criteria

• Healthy non-smokers and smokers

• Upper respiratory infection within the last 4 weeks.
• Subjects who have received research medication within the previous one month.
• Subjects unable to give informed consent.
• Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study Stable COPD patients
• Patients who have had an exacerbation which required treatment with oral steroids during the last 2 months prior to the visit
• Upper respiratory infection within the last 4 weeks
• Subjects who have received research medication within the previous one month
• Subjects unable to give informed consent
• Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study COPD patients with acute exacerbation
• Subjects who have received research medication within the previous one month
• Subjects unable to give informed consent
• Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study Asthma
• Upper respiratory infection within the last 4 weeks
• Subjects who have received research medication within the previous one month
• Subjects unable to give informed consent.
• Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study.
• Bronchiectasis and cystic fibrosis

• Subjects who have received research medication within the previous one month.
• Subjects unable to give informed consent.
• Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study.